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Background: Folate receptor alpha (FOLR1/FRA) is expressed in a number of epithelial cancers and in particular
epithelial ovarian cancer (EOC), especially of the serous histotype. Recent studies have shown that EOC originates
from the fallopian tube fimbriae rather than from epithelial cells lining the ovary. We have previously shown by
immunohistochemistry a strong correlation between FRA expression in EOC and normal and fallopian
adenocarcinoma. Folate receptor beta (FOLR2/FRB) has been described to be expressed by macrophages both in
inflammatory disorders and certain epithelial cancers. Given the high sequence identity of these two folate
receptor family members we sought to investigate the architectural and cell-specific expression of these two
receptors in gynecologic tissues.
Methods: RNA scope, a novel chromogenic in situ hybridization assay tool, was used to examine expression of
the alpha (FOLR1) and beta (FOLR2) isoforms of folate receptor relative to each other as well as to the
macrophage markers CD11b and CD68, in samples of normal fallopian tube and fallopian adenocarcinoma as
well as normal ovary and EOC.
Results: We demonstrated expression of both FOLR1 and FOLR2 in EOC, normal fallopian tube and fallopian
adenocarcinoma tissue while very little expression of either marker was observed in normal ovary. Furthermore,
FOLR2 was shown to be expressed almost exclusively in macrophages, of both the M1 and M2 lineages, as
determined by co-expression of CD11b and/or CD68, with little or no expression in epithelial cells.
Conclusions: These findings further substantiate the hypothesis that the cell of origin of EOC is tubal epithelium
and that the beta isoform of folate receptor is primarily restricted to macrophages. Further, macrophages
expressing FOLR2 may represent tumor associated or infiltrating macrophages (TAMs) in epithelial cancers.
Keywords: FOLR1, FOLR2, CD68, CD11b, Epithelial ovarian cancer, Fallopian adenocarcinoma, Tumor
microenvironment, Stromal cellsBackground
Ovarian cancer causes more deaths than any other can-
cer of the female reproductive system [1]. Delayed diag-
nosis and the presence of widely disseminated disease
contribute to the high mortality associated with the dis-
ease. Efforts continue in an attempt to understand the
underlying molecular mechanisms of the pathogenesis of* Correspondence: doshannessy@morphotek.com
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order to identify new targets for potential therapy and
new modes of diagnosis.
It was previously thought that epithelial ovarian cancer
(EOC) derived from epithelial cells covering the ovary
[5, 6]. However, recent studies have shown that most
EOCs do not exhibit characteristics typical of mesoder-
mal epithelium from which the ovaries develop. There-
fore, it has been hypothesized that EOCs, particularly
those of the serous histotype, originate from theess article distributed under the terms of the Creative Commons Attribution
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which may or may not already exist in a (pre) cancer-
ous state [7–12]. The tubal epithelium, along with other
reproductive organs, derives from the müllerian duct,
which in turn is derived from the mesoderm.
Previous work within our laboratory, based on immu-
nohistochemical detection of folate receptor alpha
(FRA), has shown a strong correlation between ovarian
serous carcinomas (EOC) and normal fallopian tube as
well as fallopian adenocarcinoma [13] with respect to ex-
pression of this receptor. In addition, gene expression
analysis has demonstrated that numerous genes previ-
ously considered to be (over) expressed in EOC (e.g.
FOLR1, MSLN, MUC16 and WFDC2) are indeed signifi-
cantly overexpressed in EOC when compared to normal
ovarian tissue yet none of these genes/markers of EOC
showed significantly increased expression when compared
to either normal fallopian tube or fallopian adenocarcin-
oma tissues [14]. These data support the hypothesis that
EOC derives from fallopian fimbriae and, further, that
markers previously considered to be up-regulated or over
expressed in EOC are most likely not of ovarian origin,
but fallopian in derivation. The increased serum levels of
the protein biomarker products of these genes (FRA,
mesothelin, CA125 and HE4) in ovarian cancer may
therefore be more a reflection of disease (tissue) burden
than either tumor specific markers or over expression.
However, it should be noted that expression profiles are
most often devoid of architectural context and differences
may be partly attributable to, or confounded by, the het-
erogeneity of cell types, and the relative contributions
there from, that are potentially present (e.g. normal epithe-
lia, stromal cells, and tumor) within tissue sections. We
therefore undertook an investigation into the expression
of FOLR1 (folate receptor alpha, FRA) and FOLR2 (folate
receptor beta, FRB) in gynecologic tissues, both normal
and malignant, relative to architectural features and cellu-
lar specificity using dual-color RNA in situ hybridization.
Folate receptors alpha (FRA) and beta (FRB) are glyco-
sylphosphatidylinositol (GPI)-anchored receptors that
bind plasma folate (5-methyltetrahydrofolate) with high
affinity (KD ~1nM), and transport it into the cell via
endocytosis [15]. FRA and FRB exhibit 71 % identity at
the amino acid level (Fig. 1) and lie in tandem on
chromosome 11q13, along with two other members of
this family, folate receptor gamma and folate receptor
delta, although much less is known about these two
family members. Although closely related both in func-
tion and sequence, the tissue distribution and cellular
specificity of FRA and FRB are quite distinct. FRA, the
most extensively studied isotype, is expressed on several
tumors of epithelial origin including ovarian cancer,
non-small cell lung adenocarcinoma, breast cancer,
renal cancer and endometrial cancer [16–21]. Further,FRA has been shown to be expressed in normal placenta,
fallopian tube, kidney, lung, breast and choroid plexus. In
contrast, FRB expression appears to be restricted predom-
inately to hematopoietic cells. FRB was recently described
as a marker of pro-inflammatory monocytes [22] and has
further been described as a marker of tumor associated
macrophages (TAMs; tumor infiltrating leukocytes or
TILs) and of M2 anti-inflammatory/regulatory macro-
phages [23, 24].
Tumor progression and metastasis are dependent on
the interaction/cross-talk of epithelial cells and stromal
cells [25], i.e. is architecturally and contextually
dependent and determined. The stromal cell compart-
ment is comprised of activated endothelial cells, im-
mune cells, fibroblasts, and bone marrow-derived cells.
Inflammatory cells, or leucocytes, including neutro-
phils, macrophages, monocytes, granulocytes and nat-
ural killer cells, have been implicated in tumor cell
growth and metastasis [26–32]. Given the distinct cell-
type specificity of expression of FRA and FRB, and the
role of infiltrating or tumor associated inflammatory
cells on the growth and metastasis of tumors, we
sought to examine tumor and immune cell expression
of both FRA and FRB in the context of gynecologic tis-
sues, in particular EOC, using RNAscope, a novel,
semi-quantitative, nucleic acid in situ hybridization
(ISH) tool that allows for single molecule signal ampli-
fication and background suppression of individual cells
[33] to evaluate, in architectural context, the expression
patterns of FOLR1 and FOLR2. Further, the expression
of FOLR1 and FOLR2 were assessed in context to the
expression of CD11b and CD68, used as markers for
M1 and M2 macrophages, respectively [34].
Methods
Sample description
Formalin-fixed paraffin embedded (FFPE) tissue sam-
ples were obtained from Asterand, Inc. All institutions
participating in this study had Institutional Review
Board (IRB) approval for human subject research. Nor-
mal ovary and fallopian tube tissue samples were ac-
quired from unrelated donors with no previous history
of cancer. Sample demographics are presented in
Table 1.
RNAscope probes
Paired double-Z oligonucleotide probes were designed
against target RNA using custom software as described
previously [33, 35]. GenBank accession numbers, number
of probe pairs, and probe regions were: FOLR1,
NM_016729.2, 15 pairs, nt 2–966; FOLR2, NM_000803.4,
16 pairs, nt 30–1098; CD11b, NM_001145808.1, 20 pairs,
nt 2356–3240; CD68, NM_001040059.1, 20 pairs, nt 70–
1149. Probes were designed to be used in the following
Fig. 1 Partial sequences for the 4 isoforms of human folate receptor are depicted to show the 16 conserved cysteine residues (red highlighted)
between all isoforms. FRA and FRB have 71 % identity across their entire sequences. GPI-anchored FRA has 233 amino acids. The highlighted
(blue) serine in the FRA sequence indicates the site of attachment of the GPI-anchor
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(green)/CD68 (red), FOLR1 (red)/FOLR2 (green), and
CD11b (red)/CD68 (green).
ISH using RNAscope
For detection of RNA transcripts, a commercially avail-
able kit (dual-colored RNA in situ hybridization with
RNAscope® 2-plex Chromogenic Reagent Kit, Advanced
Cell Diagnostics, Hayward, CA) was used according to
the manufacturer’s instructions. FFPE tissue blocks were
sectioned at 5 μm onto SuperFrost Plus slides (Thermo
Scientific). Slides were baked for 1 h at 60 °C prior toTable 1 Demographics and clinical characteristics of donors
Variable Ovarian (%) Fallopian Tube (%)
Tumor Histology
Normal 5 10
Serous carcinoma 20 10
Age (Mean, SD) 53.2, 12.1 49.6, 12.6
Race
White/Caucasian 25 10
Black/African American 0 0
Native American/Alaskan 0 0
Unspecified 0 0
Tumor Grade1
High 13 (65) 4 (40)
Low 7 (35) 4 (40)
Unspecified 0 (0) 2 (20)
Tumor Stage1,2
Stage I 8 (40) 1 (10)
Stage II 4 (20) 0 (0)
Stage III 1 (5) 8 (80)
Unspecified 7 (35) 1 (10)
1 Numbers and Percentages exclude Normal Tissues
2 Tumor staging was determined using the International Federation of
Gynecology and Obstetrics (FIGO) staging systemuse. After de-paraffinization and dehydration, the tissues
were air dried and treated with peroxidase blocker be-
fore boiling at 100–104 °C in a pretreatment solution for
15 min. Protease was then applied for 30 min at 40 °C.
Target probes (FOLR1, FOLR2, CD11b, CD68) for each
two-gene combination were premixed and hybridized to-
gether for 2 h at 40 °C, followed by a series of signal
amplification and washing steps. All hybridizations at
40 °C were performed in a HybEZ Hybridization System.
Hybridization signals were detected by sequential
chromogenic reactions using red and green chromogens.
RNA staining signal was identified as red and green
punctate dots.
Following the RNAscope assay, samples were counter-
stained for 2 min with 50 % Gill’s Hematoxylin diluted
in dH20. Each sample was quality controlled for RNA in-
tegrity with a probe specific to the housekeeping gene
cyclophilin B (PPIB); only samples with an average of >4
dots per cell were included for analysis. Negative control
background staining was evaluated using a probe specific
to the bacterial dapB gene; only samples with an average
of <1 dot per 10 cells were included for analysis. To ver-
ify that the RNAscope method was performed with tech-
nical accuracy, references slides consisting of FFPE HeLa
cell pellets were tested with PPIB and dapB in parallel
with tissue samples. Bright field images were acquired
using a Zeiss Axio Imager M1 microscope using a 40×
objective.
Results
Co-expression studies using markers for FOLR1 and
FOLR2
FOLR1 and FOLR2 transcripts were detected by dual
color staining. In normal fallopian tube, FOLR1 was al-
most exclusively expressed, at relatively high levels, in
columnar epithelium (Fig. 2a), consistent with published
IHC data [13]. The stromal compartment was negative
for FOLR1 expression. The majority of the epithelial






Fig. 2 Expression of FOLR1 and FOLR2 were detected by dual color staining for FOLR1 (red) and FOLR2 (green) mRNA in normal fallopian tube (Fig. 2a),
normal ovary (Fig. 2b), fallopian adenocarcinoma (Fig. 2c, d), and epithelial ovarian cancer (EOC) (Fig. 2e, f). Images are 40x magnification
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cells, FOLR2 was detected in columnar epithelia but at sig-
nificantly lower levels, represented by lower FOLR2 signal
dots, relative to FOLR1 expression. In contrast to normal
fallopian tube, normal ovary showed very low levels of ei-
ther FOLR1 or FOLR2 mRNA (Fig. 2b) in either the epithe-
lial or stromal compartments. These data are consistent
with previous studies on the lack of expression of FRA as
determined by IHC in normal ovary but extend such stud-
ies to the co-expression of these highly related receptors.In fallopian tube adenocarcinoma, FOLR1expression
was again limited to epithelia, in this instance tumor
cells, and showed variable, but consistently high, expres-
sion levels (Fig.2c, d). In some cases, FOLR1 expression
in fallopian tube adenocarcinoma appeared more highly
expressed relative to normal fallopian tube, suggesting
the potential of increased expression of FOLR1 mRNA
(Fig. 2d). However, it should be noted that the present
study was not designed to either determine nor quantify
expression levels per se and normal and tumor samples
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observation should be interpreted with caution.
Importantly, FOLR2 mRNA was strongly expressed by
certain stromal cells surrounding the tumor cells of fal-
lopian adenocarcinoma samples (Fig. 2d) but not the
tumor cells themselves. Similar to fallopian tube normal
and adenocarcinoma samples, and in contract to normal
ovary, EOC showed abundant expression of FOLR1
mRNA (Fig. 2e, f ) in the epithelial tumor cells whereas
FOLR2 expression was restricted to stromal cells.
Co-expression studies using markers for macrophages
Given the observation that the expression of FOLR2 is
primarily restricted to stromal cells, and since FOLR2
has been described as being expressed in macrophages,
we sought to determine if FOLR2 expression in gyneco-
logic tissues could be ascribed to macrophages. For this
purpose the macrophage markers CD11b and CD68
were used in combination with FOLR2 probes in both
normal and tumor tissues. In normal fallopian tube
some scattered CD11b/CD68 positive cells were ob-
served in the stromal region and aggregation of CD11b/
CD68 expressing cells were frequently found in the
lumen of fallopian tubes, as shown in Fig. 3a. CD11b
positive cells demonstrated strong FOLR2 expression
and were also positive for CD68. Normal ovary showed
relatively low expression of FOLR2 (Fig. 3b). Import-
antly, CD11b/CD68 positive cells were observed sur-
rounding the tumors cells in fallopian adenocarcinoma
(Fig. 3c) and in EOC (Fig. 3d), suggesting these cells may
represent tumor associated macrophages (TAMs). Dual
color staining for CD68/FOLR2 showed some macro-
phages expressed FOLR2 in fallopian adenocarcinoma
(Fig. 3e) and EOC (Fig. 3f ).
Discussion
In the present study we used RNAscope to investigate
the spatial expression of the alpha and beta isoforms of
folate receptor (FOLR1 and FOLR2, respectively), rela-
tive to each other, as well as in context to macrophages
using markers for CD11b and CD68. The tissues investi-
gated were normal ovarian and fallopian tube as well as
EOC and fallopian adenocarcinoma, all as FFPE slides.
The data demonstrated that FOLR1 (folate receptor
alpha; FRA) was highly expressed in epithelial cells of
normal fallopian tube but rarely detectable in normal
ovarian epithelial cells. In addition, epithelial cells of
both fallopian adenocarcinoma and EOC showed high
levels of FOLR1 expression. These data are consistent
with previous studies, using both immunohistochemistry
[13] and global RNA expression analyses [14], and sup-
port the contention that FRA is normally expressed in
fallopian tube, but not ovary, and that EOC derives from
fallopian fimbriae.In contrast to FOLR1 expression, FOLR2 was only
weakly expressed in all samples tested. As with FOLR1,
FOLR2 was rarely detectable in normal ovarian tissue.
EOC, normal fallopian tube and fallopian adenocarcin-
oma showed some expression of FOLR2, which agrees
with a study by Gaytan et al. [36], which showed that
macrophages were present in both fallopian tube and
epithelial inclusion cysts but were not present in normal
ovarian surface epithelium. The low level expression of
FOLR2 in gynecologic tissues was clearly spatially dis-
tinct from FOLR1. While FOLR1 was expressed almost
exclusively in epithelial cells, FOLR2 expression was pri-
marily, although not exclusively, restricted to stromal
areas, especially evident in normal fallopian tube tissue.
Since FOLR2 has been described to be expressed by
macrophages, we sought to employ duplex RNAscope to
investigate whether FOLR2 co-expressed with known
macrophage markers CD11b and/or CD68. Using probes
for CD11b and CD68 resulted in two apparently distinct
populations of macrophages with some cells expressing
both markers while others appeared to express only one
marker. Significantly more cells were positive for CD68
than were positive for CD11b. Using duplex assays with
FOLR2 and each of CD11b and CD68 separately, dem-
onstrated that FOLR2 was expressed in both cell types
but appeared to be more closely linked to the expression
of CD68, possibly a reflection of the number of CD68+
cells. Regardless, FOLR2 expression was rarely seen in
the absence of either CD11b or CD68 positivity support-
ing previous observations that FOLR2 (folate receptor
beta) is expressed in hematopoietic cells of the macro-
phage M1 or M2 phenotype.
Folate receptor beta has been described to be associated
with inflammatory disorders such as arthritis [37–39].
Given the association with CD68+ macrophages
described in the present work, it is worthy of specula-
tion that the FOLR2 macrophages identified in the
EOC and fallopian adenocarcinoma samples represent
TAMs (tumor associated macrophages or tumor infil-
trating macrophages) and that folate receptor beta may
indeed be a marker of this cell population. Since folate
receptor alpha is expressed exclusively by the epithelial
cells themselves in these tumors, we can now link the
expression of these 2 isoforms of folate receptor to the
pathogenesis of cancer. Of course, the present data
does not rule out that both folate receptors may, at
least in some instances, be expressed by the same cell,
but the present data would suggest that this would rep-
resent a minor fraction of total expression.
Given the role of immune cells on cancer growth and
progression, this study also examined the co-expression
of tumor cells with macrophage markers in patients with
ovarian or fallopian tube cancer, using RNAscope.






Fig. 3 Expression of macrophage marker CD11b (red) in combination with FOLR2 (green) in normal fallopian tube (Fig. 3a) and normal ovary (Fig. 3b).
Expression of macrophage markers CD11b (red) and CD68 (green) in fallopian adenocarcinoma (Fig. 3c) and EOC (Fig. 3d). Expression of macrophage
marker CD68 (red) in combination with FOLR2 (green) in fallopian adenocarcinoma (Fig. 3e) and EOC (Fig. 3f). Images are 40x magnification
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well documented that formation of solid tumors requires
the proliferation of stromal cells to support cancer cell
growth, invasion and metastasis. The stromal cell com-
partment is comprised of activated endothelial cells, im-
mune cells, fibroblasts, and bone marrow-derived cells.
These cells support the growth and maintenance of
tumor cells by providing a microenvironment to supply
blood and nutrients to tumor cells. Inflammatory cells,including neutrophils, macrophages, monocytes, granu-
locytes and natural killer cells, have been implicated in
tumor cell growth and metastasis [28–32, 40].
Neutrophils and macrophages participate in defense
mechanisms that protect the host against injury and in-
fection. However, activation of these immune cells has
also been shown to affect tumor cell growth and prolif-
eration. Neutrophils secrete products, such as reactive
oxygen species (ROS) and proteinases, that have defined
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angiogenesis, and metastasis. ROS production results in
activation of macrophages, which results in polarization
to pro-inflammatory (M1) or anti-inflammatory (M2)
states with distinct phenotypes and physiological re-
sponses. The classical pro-inflammatory M1 phenotype
is induced by LPS and interferon-γ (IFN-γ), whereas the
alternative M2 phenotype is induced by IL-4 and IL-13.
The M1 state is characterized by increased expression of
pro-inflammatory cytokines as well as microbicidal ac-
tivity, while M2 macrophages upregulate the anti-
inflammatory cytokine IL-10 and participate in tissue re-
modeling, wound repair, and host defense against large
parasites. Most macrophages of the M2 phenotype are
considered Tumor Activated/Associated Macrophages,
or TAMs, and are associated with cancer progression
and are recruited from peripheral blood by chemokines
and then positioned in the tumor stroma. TAMs inter-
act with endothelial cells and are also involved in
angiogenesis.
In the present study, immune cells were analyzed by
examining markers such as CD11b (marker for M1 mac-
rophages), or FOLR2 and CD68 (marker for M2 macro-
phages). CD11b is a B2 integrin family member that
pairs with CD18 to form the CR3 heterodimer on the
cell surface of neutrophils and M1 macrophages. Upon
activation, immune response results in translocation of
CD11b/CD18 from granules to the plasma membrane
[41–43]. CD68 is a glycoprotein on low density lipopro-
teins found on the M2 phenotype of macrophages.
FOLR2 encodes the gene product folate receptor beta
and has been shown to be expressed on the M2 pheno-
type of tumor associated macrophages, or TAMs.
We observed good expression of the M2 macrophage
markers, CD68 and FOLR2, in EOC, normal fallopian
tube and fallopian adenocarcinoma and significantly
lower expression of the M2 markers in normal ovary. All
four tissues showed co-localization of CD68 and FOLR2,
which is to be expected since FOLR2 and CD68 are anti-
gens for the M2 phenotype of macrophages. In addition,
studies have previously shown that macrophages positive
for FOLR2 are also positive for CD68 [23] CD68+ mac-
rophages were expressed at slightly higher levels in nor-
mal fallopian tube, fallopian adenocarcinoma and EOC
than FOLR2+ macrophages, but this is not surprising since
CD68 may recognize both M1 and M2 macrophages [44].
Recent studies have shown that FOLR2-expressing macro-
phages comprise a specific subset among the total popula-
tion of tumor infiltrating macrophages [45]. Although
FOLR2 and CD68 co-localized in normal ovarian tissues,
the expression of these markers were much lower than
those observed in EOC, normal fallopian tube or fallopian
adenocarcinoma tissues. Gaytan et al.(2007) had examined
the presence and number of macrophages in fallopiantube, epithelial inclusion cysts (EIC) and ovarian surface
epithelium (OSE), and found that macrophages were
present in both fallopian tube and EIC but were not
present in OSE [36]. We confirm this study and these data
support the hypothesis that EOC derives from fallopian
tubule fimbriae.
The co-expression studies that involved the M1 macro-
phage antigen, CD11b, and M2 macrophage antigen,
CD68, were not as clear in fallopian tube, fallopian adeno-
carcinoma or EOC. In co-expression studies of CD11b
and CD68, fallopian adenocarcinoma and EOC showed
good expression of CD68 but much lower expression of
CD11b. As a result, M1 and M2 macrophages did not ap-
pear to co-localize in these tissues. However, both CD11b
and CD68 are non-selective markers for macrophages,
and may not completely distinguish between M1 and M2
macrophages. In addition CD68 has also been shown to
recognize satellite cells and fibroblasts and CD11b has
been shown to recognize neutrophils. This suggests that
the markers should not be used to distinguish quantity or
type of macrophages [46]. Irrespective of these complica-
tions relative to the specificity of these markers, CD11b
and CD68 were not expressed in normal ovary. Import-
antly, the similarities between EOC and fallopian tube,
both normal and adenocarcinoma, are striking and lend
further support to the fallopian tube as the origin of epi-
thelial ovarian cancer.
Clinical development programs employing monoclonal
antibodies specific for either folate receptor alpha in cer-
tain cancers of epithelial origin, including EOC, and fol-
ate receptor beta in inflammatory disorders such as
arthritis, are underway. Given the apparent cell-type spe-
cificity of these two highly related proteins, as shown
here, and given the involvement of TAMs in solid tumor
progression, it is interesting to consider the potential of
combining these two targeted approaches for the treat-
ment of cancers such as EOC. Finally, since both recep-
tors bind folates with high affinity and distinctly from
the reduced folate carrier (RFC), it is feasible that small
molecule drugs could be designed and developed to spe-
cifically target both receptors simultaneously.
Conclusions
Using RNAscope, a novel ISH method, we confirmed
the similarities between EOC and fallopian tube, normal
and adenocarcinoma using FOLR1, FOLR2, CD68 and
CD11b markers. As a result, these findings further sup-
port the hypothesis that EOC is derived from fallopian
tube. In addition, this method showed that the beta iso-
form of folate receptor is primarily restricted to macro-
phages. RNA in situ hybridization using RNAscope
shows promise with respect to furthering our under-
standing of both the origin and pathogenesis of ovarian
and other solid tumors.
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